PICKERING GRANT 4

4 · Vaxcyte, Inc. · Filed Dec 10, 2024

Form 4

Period: 2024-12-09

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Sale
Common Stock
2024-12-09$93.10/sh−222$20,668→ 136,215 total(indirect: By Trust)
Sale
Common Stock
2024-12-09$92.06/sh−961$88,470→ 136,437 total(indirect: By Trust)
Sale
Common Stock
2024-12-09$92.03/sh−1,029$94,701→ 136,369 total(indirect: By Trust)
Sale
Common Stock
2024-12-09$93.60/sh−154$14,414→ 136,215 total(indirect: By Trust)

Holdings

Footnotes (7)

[F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024.
[F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $91.615 to $92.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
[F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $92.80 to $93.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]The price reported is a weighted-average price. The shares were sold at prices ranging from $91.715 to $92.63. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F6]Shares are held directly by a trust for the benefit of the Reporting Person's son.
[F7]The price reported is a weighted-average price. The shares were sold at prices ranging from $93.355 to $93.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Documents

1 file